Ahmet Serhan Dağıstanlı

Dr. Ahmet Serhan Dağıstanlı

Istanbul University Faculty of Medicine, Pulmonology
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MEMustafa Erelel
Mustafa Erelel
MKMert Kaşkal
Mert Kaşkal
ODOZLEM AKBAL DAGISTAN
OZLEM AKBAL DAGISTAN
HİHalim İşsever
Halim İşsever
Ahmet Serhan DağıstanlıAhmet Serhan Dağıstanlı
Ahmet Serhan Dağıstanlı
Ayca Yildiz-PekozAyca Yildiz-Pekoz
Ayca Yildiz-Pekoz
In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler.